Systematic review · people
PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety data
Checked against the paper Systematic reviewPublished by PepVault
The takeaway
Nausea is the side effect most likely to show up on bremelanotide and the main reason people quit; blood pressure bumps were small and brief, and the authors advise care for people at risk of heart disease.
- Kind
- Systematic review
- Studied in
- People
- Number studied
- 3500
- Published
- 2022
- Journal
- J Womens Health (Larchmt)
What they tested
The team set out to describe the side effects and safety of bremelanotide across its whole clinical program, from phase 1 through phase 3.
How the study was done
A review of safety data from 43 completed studies with 3500 people, including a pooled look at the double-blind, placebo-controlled part of the phase 3 studies in 1247 people. In phase 3, people used bremelanotide for up to 18 months.

What they found
In the pooled phase 3 data, nausea was the most common side effect (40.0% on bremelanotide vs 1.3% on placebo, a dummy shot), followed by flushing (20.3% vs 1.3%), headache (11.3% vs 1.9%) and injection site reactions (5.4 vs 0.5). Nausea was the top reason people stopped the drug, and 70% of the bremelanotide group moved on to the open-label phase vs 87% of the placebo group. No one died, and a few people had serious side effects. Patches of darkened skin were rare at label dosing but showed up in more than one-third of people given up to 16 daily doses in a row, and blood pressure rose slightly for a short time during ambulatory monitoring, meaning readings taken as people went about their day.
What it doesn’t show
This is a safety review, so it does not show how well the drug works. The darkened skin result came from daily dosing outside the label schedule, and the long-term data reach only 18 months.
The paper
Clayton et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022.
The compound
More studies on PT-141
- PT-141: side-effect dropouts far higher than placebo in re-analysisMeta-analysis · people · 2021
- PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeksRandomized trial · people · 2016
- Every study on PT-141
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.